Ignite Creation Date:
2024-05-06 @ 2:47 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04422912
Status:
RECRUITING
Last Update Posted:
2024-05-22
First Post:
2020-06-02
Brief Title:
A Phase 12 Open-label Safety and Dosing Study of Autologous CART Cells Desmoglein 3 Chimeric Autoantibody Receptor T Cells DSG3-CAART or CD19-specific Chimeric Antigen Receptor T Cells CABA-201 in Subjects With Active Pemphigus Vulgaris RESET-PV
Sponsor:
Organization:
Cabaletta Bio
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
55
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: